LAVAL, QC, Feb. 21 /CNW Telbec/ - In light of Neurochem Inc.'s
(NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the
departure, effective February 21, 2008, of two members of its senior
management team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President,
Strategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice
President, Business Development. The possibility of their acting as
consultants in respect of specific projects is being explored.
"On behalf of the Board of Directors and my colleagues, I want to express
our gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable
contribution to Neurochem. We wish them every success in the future," said
Dr. Francesco Bellini, Neurochem's Chairman, President and CEO.
Neurochem Inc. is a global health company focused on the research,
development and commercialization of products to provide innovative health
solutions to address critical unmet medical needs.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical and/or
nutraceutical industry, changes in the regulatory environment in the
jurisdictions in which the Neurochem group does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, that actual results may vary once the final and
quality-controlled verification of data and analyses has been completed, as
well as other risks disclosed in public filings of Neurochem Inc.
Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. The reader should not
place undue reliance, if any, on any forward-looking statements included in
this news release. These statements speak only as of the date made and
Neurochem Inc. is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise,
unless required by applicable legislation or regulation. Please see the Annual
Information Form of Neurochem Inc. for further risk factors that might affect
the Neurochem group and its business.
For further information:
For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4572, firstname.lastname@example.org